CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
TSX:CPH • CA17253X1050
15.49 CAD
+0.08 (+0.52%)
Last: Feb 25, 2026, 07:00 PM
Taking everything into account, CPH scores 7 out of 10 in our fundamental rating. CPH was compared to 33 industry peers in the Pharmaceuticals industry. CPH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CPH is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make CPH suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- In the past year CPH was profitable.
- In the past year CPH had a positive cash flow from operations.
- Each year in the past 5 years CPH has been profitable.
- CPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- CPH has a Return On Assets of 11.77%. This is amongst the best in the industry. CPH outperforms 90.91% of its industry peers.
- The Return On Equity of CPH (15.23%) is better than 87.88% of its industry peers.
- CPH has a Return On Invested Capital of 7.23%. This is amongst the best in the industry. CPH outperforms 87.88% of its industry peers.
- CPH had an Average Return On Invested Capital over the past 3 years of 8.42%. This is in line with the industry average of 8.54%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
- Looking at the Profit Margin, with a value of 34.68%, CPH belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- CPH's Profit Margin has improved in the last couple of years.
- With an excellent Operating Margin value of 25.51%, CPH belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
- CPH's Operating Margin has declined in the last couple of years.
- CPH has a better Gross Margin (74.32%) than 93.94% of its industry peers.
- In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CPH is destroying value.
- Compared to 1 year ago, CPH has more shares outstanding
- The number of shares outstanding for CPH has been reduced compared to 5 years ago.
- The debt/assets ratio for CPH is higher compared to a year ago.
2.2 Solvency
- CPH has an Altman-Z score of 6.63. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
- CPH has a better Altman-Z score (6.63) than 93.94% of its industry peers.
- CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 0.45, CPH belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
- CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
- CPH's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CPH outperforms 69.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.63 |
ROIC/WACC0.85
WACC8.54%
2.3 Liquidity
- A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
- CPH's Current ratio of 1.30 is on the low side compared to the rest of the industry. CPH is outperformed by 69.70% of its industry peers.
- CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
- CPH has a Quick ratio (0.98) which is comparable to the rest of the industry.
- The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
- CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
- Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.97% on average per year.
- The Revenue has grown by 89.17% in the past year. This is a very strong growth!
- CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
- The Earnings Per Share is expected to grow by 20.66% on average over the next years. This is a very strong growth
- Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 27.91% on average per year.
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 17.21, the valuation of CPH can be described as rather expensive.
- CPH's Price/Earnings ratio is rather cheap when compared to the industry. CPH is cheaper than 81.82% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.05, CPH is valued a bit cheaper.
- A Price/Forward Earnings ratio of 28.72 indicates a quite expensive valuation of CPH.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 63.64% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.03. CPH is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.21 | ||
| Fwd PE | 28.72 |
4.2 Price Multiples
- CPH's Enterprise Value to EBITDA ratio is in line with the industry average.
- Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than 78.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.56 | ||
| EV/EBITDA | 14.77 |
4.3 Compensation for Growth
- CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- CPH has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as CPH's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)0.33
PEG (5Y)1.33
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
- No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (2/25/2026, 7:00:00 PM)
15.49
+0.08 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-12 2026-03-12
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap391.59M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts80
Price Target19.58 (26.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0%
PT rev (3m)6.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)10.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.21 | ||
| Fwd PE | 28.72 | ||
| P/S | 5.71 | ||
| P/FCF | 9.56 | ||
| P/OCF | 9.53 | ||
| P/B | 2.51 | ||
| P/tB | 12.52 | ||
| EV/EBITDA | 14.77 |
EPS(TTM)0.9
EY5.81%
EPS(NY)0.54
Fwd EY3.48%
FCF(TTM)1.62
FCFY10.46%
OCF(TTM)1.62
OCFY10.49%
SpS2.71
BVpS6.17
TBVpS1.24
PEG (NY)0.33
PEG (5Y)1.33
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.63 |
F-Score7
WACC8.54%
ROIC/WACC0.85
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year140.63%
EBIT Next 3Y50.89%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status for CPH stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
What is the profitability of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 17.21 and the Price/Book (PB) ratio is 2.51.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.